Title: Full Text of HB1102
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Full Text of HB1102 ILGA.GOV HB1102 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB1102 Introduced 1/9/2025, by Rep. Jed Davis SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u    Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.LRB104 03831 BAB 13855 b  A BILL FOR HB1102LRB104 03831 BAB 13855 b1    AN ACT concerning regulation. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Insurance Code is amended by 5changing Section 356u as follows: 6    (215 ILCS 5/356u)7    Sec. 356u. Pap tests and prostate cancer screenings. 8    (a) A group policy of accident and health insurance that 9provides coverage for hospital or medical treatment or 10services for illness on an expense-incurred basis and is 11amended, delivered, issued, or renewed after January 1, 2024 12shall provide coverage, without imposing a deductible, 13coinsurance, copayment, or any other cost-sharing requirement, 14for all of the following:15        (1) An annual cervical smear or Pap smear test for all 16    insureds.17        (2) An annual prostate cancer screening for insureds 18    upon the recommendation of a physician licensed to 19    practice medicine in all its branches for:20            (A) asymptomatic individuals age 50 and over;21            (B) African-American individuals age 40 and over; 22        and23            (C) individuals age 40 and over with a family   HB1102- 2 -LRB104 03831 BAB 13855 b1        history of or genetic predisposition to prostate 2        cancer.3        (3) Surveillance tests for ovarian cancer for insureds 4    who are at risk for ovarian cancer.5    (b) This Section shall not apply to agreements, contracts, 6or policies that provide coverage for a specified disease or 7other limited benefit coverage.8    (c) This Section does not apply to coverage of prostate 9cancer screenings to the extent such coverage would disqualify 10a high-deductible health plan from eligibility for a health 11savings account pursuant to Section 223 of the Internal 12Revenue Code. 13    (d) For the purposes of this Section:14    "At risk for ovarian cancer" means:15        (1) having a family history (i) with one or more 16    first-degree relatives with ovarian cancer, (ii) of 17    clusters of relatives with breast cancer, or (iii) of 18    nonpolyposis colorectal cancer; or19        (2) testing positive for BRCA1 or BRCA2 mutations; or .20        (3) having a high level of CA-125, as indicated by a 21    blood test screening. 22    "Prostate cancer screening" means medically viable methods 23for the detection and diagnosis of prostate cancer, including 24a digital rectal exam and the prostate-specific antigen test 25and associated laboratory work. "Prostate cancer screening" 26includes medically necessary subsequent follow-up testing as   HB1102- 3 -LRB104 03831 BAB 13855 b1directed by a health care provider, including, but not limited 2to:3        (1) urinary analysis;4        (2) serum biomarkers; and5        (3) medical imaging, including, but not limited to, 6    magnetic resonance imaging. 7    "Surveillance tests for ovarian cancer" means all 8medically viable methods for the detection and diagnosis of 9ovarian cancer, including, but not limited to, ultrasounds, 10magnetic resonance imagings (MRIs), x-rays, computed 11tomography (CT) scans, and CA-125 blood test screenings. 12annual screening using (i) CA-125 serum tumor marker testing, 13(ii) transvaginal ultrasound, (iii) pelvic examination. 14(Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25.) 15    Section 99. Effective date. This Act takes effect January 161, 2027.


================================================================================

Raw Text:
Full Text of HB1102 ILGA.GOV HB1102 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB1102 Introduced 1/9/2025, by Rep. Jed Davis SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u    Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.LRB104 03831 BAB 13855 b  A BILL FOR HB1102LRB104 03831 BAB 13855 b1    AN ACT concerning regulation. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Insurance Code is amended by 5changing Section 356u as follows: 6    (215 ILCS 5/356u)7    Sec. 356u. Pap tests and prostate cancer screenings. 8    (a) A group policy of accident and health insurance that 9provides coverage for hospital or medical treatment or 10services for illness on an expense-incurred basis and is 11amended, delivered, issued, or renewed after January 1, 2024 12shall provide coverage, without imposing a deductible, 13coinsurance, copayment, or any other cost-sharing requirement, 14for all of the following:15        (1) An annual cervical smear or Pap smear test for all 16    insureds.17        (2) An annual prostate cancer screening for insureds 18    upon the recommendation of a physician licensed to 19    practice medicine in all its branches for:20            (A) asymptomatic individuals age 50 and over;21            (B) African-American individuals age 40 and over; 22        and23            (C) individuals age 40 and over with a family   HB1102- 2 -LRB104 03831 BAB 13855 b1        history of or genetic predisposition to prostate 2        cancer.3        (3) Surveillance tests for ovarian cancer for insureds 4    who are at risk for ovarian cancer.5    (b) This Section shall not apply to agreements, contracts, 6or policies that provide coverage for a specified disease or 7other limited benefit coverage.8    (c) This Section does not apply to coverage of prostate 9cancer screenings to the extent such coverage would disqualify 10a high-deductible health plan from eligibility for a health 11savings account pursuant to Section 223 of the Internal 12Revenue Code. 13    (d) For the purposes of this Section:14    "At risk for ovarian cancer" means:15        (1) having a family history (i) with one or more 16    first-degree relatives with ovarian cancer, (ii) of 17    clusters of relatives with breast cancer, or (iii) of 18    nonpolyposis colorectal cancer; or19        (2) testing positive for BRCA1 or BRCA2 mutations; or .20        (3) having a high level of CA-125, as indicated by a 21    blood test screening. 22    "Prostate cancer screening" means medically viable methods 23for the detection and diagnosis of prostate cancer, including 24a digital rectal exam and the prostate-specific antigen test 25and associated laboratory work. "Prostate cancer screening" 26includes medically necessary subsequent follow-up testing as   HB1102- 3 -LRB104 03831 BAB 13855 b1directed by a health care provider, including, but not limited 2to:3        (1) urinary analysis;4        (2) serum biomarkers; and5        (3) medical imaging, including, but not limited to, 6    magnetic resonance imaging. 7    "Surveillance tests for ovarian cancer" means all 8medically viable methods for the detection and diagnosis of 9ovarian cancer, including, but not limited to, ultrasounds, 10magnetic resonance imagings (MRIs), x-rays, computed 11tomography (CT) scans, and CA-125 blood test screenings. 12annual screening using (i) CA-125 serum tumor marker testing, 13(ii) transvaginal ultrasound, (iii) pelvic examination. 14(Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25.) 15    Section 99. Effective date. This Act takes effect January 161, 2027.